Anti-trypanosomatid drug discovery: progress and challenges
Leishmaniasis (visceral and cutaneous), Chagas disease and human African
trypanosomiasis cause substantial death and morbidity, particularly in low-and middle …
trypanosomiasis cause substantial death and morbidity, particularly in low-and middle …
Is leishmaniasis the new emerging zoonosis in the world?
E Montaner-Angoiti, L Llobat - Veterinary Research Communications, 2023 - Springer
Leishmania is a genus of parasitic protozoa that causes a disease called leishmaniasis.
Leishmaniasis is transmitted to humans through the bites of infected female sandflies. There …
Leishmaniasis is transmitted to humans through the bites of infected female sandflies. There …
Engineering and design of promising T-cell-based multi-epitope vaccine candidates against leishmaniasis
Cutaneous leishmaniasis (CL) is a very common parasitic infection in subtropical areas
worldwide. Throughout decades, there have been challenges in vaccine design and …
worldwide. Throughout decades, there have been challenges in vaccine design and …
[HTML][HTML] Vaccine value profile for leishmaniasis
PM Kaye, G Matlashewski, S Mohan, E Le Rutte… - vaccine, 2023 - Elsevier
Leishmania infections are global, occurring in 98 countries and all World Health
Organization (WHO) regions with 600 million to 1 billion people at risk of infection. Visceral …
Organization (WHO) regions with 600 million to 1 billion people at risk of infection. Visceral …
Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis
The leishmaniases are globally important parasitic diseases for which no human vaccines
are currently available. To facilitate vaccine development, we conducted an open-label …
are currently available. To facilitate vaccine development, we conducted an open-label …
Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis
M Nateghi-Rostami, Y Sohrabi - Frontiers in Immunology, 2024 - frontiersin.org
Understanding the immune response to Leishmania infection and identifying biomarkers
that correlate with protection are crucial for developing effective vaccines. One intriguing …
that correlate with protection are crucial for developing effective vaccines. One intriguing …
Leishmaniasis vaccines: applications of RNA technology and targeted clinical trial designs
MS Duthie, BAS Machado, R Badaró, PM Kaye… - Pathogens, 2022 - mdpi.com
Leishmania parasites cause a variety of discrete clinical diseases that present in regions
where their specific sand fly vectors sustain transmission. Clinical and laboratory research …
where their specific sand fly vectors sustain transmission. Clinical and laboratory research …
Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis
This study aimed to investigate the in vitro and in silico antileishmanial activity of azacitidine
(AZA) on Leishmania major promastigotes and amastigotes. The in silico method was used …
(AZA) on Leishmania major promastigotes and amastigotes. The in silico method was used …
[HTML][HTML] Computer-aided drug design approaches applied to screen natural product's structural analogs targeting arginase in Leishmania spp
HL Barazorda-Ccahuana, LD Goyzueta-Mamani… - …, 2023 - ncbi.nlm.nih.gov
Introduction: Leishmaniasis is a disease with high mortality rates and approximately 1.5
million new cases each year. Despite the new approaches and advances to fight the …
million new cases each year. Despite the new approaches and advances to fight the …
Targeting with Structural Analogs of Natural Products the Purine Salvage Pathway in Leishmania (Leishmania) infantum by Computer-Aided Drug-Design …
HL Barazorda-Ccahuana… - Tropical Medicine and …, 2024 - mdpi.com
Visceral Leishmaniasis (VL) has a high death rate, with 500,000 new cases and 50,000
deaths occurring annually. Despite the development of novel strategies and technologies …
deaths occurring annually. Despite the development of novel strategies and technologies …